



STOCK SYMBOL
OTCQB: **CYDY**

This Database,
Revenue and
PPS is only an
example and
should not be
considered as
given.

It contains
future
assumptions
and my own
opinions!

Diseases & Data (Cytodyn's possible targets)



STOCK SYMBOL
OTCQB: **CYDY**

- Alzheimer's* <https://www.ihealthcareanalyst.com/global-alzheimers-disease-market/>
- Asthma & COPD* <https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/>
- Atherosclerosis* <https://www.thepharmaletter.com/article/atherosclerosis-drugs-market-growth>
- Atopic Dermatitis
- Cancer (22 kind)* <https://www.alliedmarketresearch.com/oncology-cancer-drugs-market>
- Coeliac Disease
- Chronic Fatigue Syndrome
- COPD COVID-19 & other Corona Vir.* <https://www.visiongain.com/report/pharma-leader-series-top-20-asthma-copd-companies-2019-2029/>
- Crohn's Disease
- Colitis
- Dermatomyositis
- Diabetes (type 1)* <https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570>
- Duchenne Musc. Dystrophy & other musc. dystrophys
- Emphysema
- Fibromyalgia* <https://www.coherentmarketinsights.com/press-release/fibromyalgia-treatment-market-to-surpass-us-36073-mn-threshold-by-2026-1385>
- Grave's Disease
- Guillain-Barre Syndrome
- GVHD * <https://www.visiongain.com/report/global-graft-versus-host-disease-gvhd-market-2019-2029/>
- Hashimoto's Thy. Hepatitis (autoimm.)
- HIV / AIDS * <https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115>
- Influenza Flu* <https://www.alliedmarketresearch.com/influenza-treatment-market-A06106>
- Idiopathic Pulmonary Fibrosis Inflammatory Bowel Disease Influenza (severe)
- Lambert-Eaton Syndrome
- Lupus
- Multiple Sclerosis* <https://www.medgadget.com/2020/02/multiple-sclerosis-drugs-market-size-growth-2020-global-analysis-by-share-value-trends-merger-business-insights-leading-players-statistics-competitive-landscape-and-regional-forecast-to-2026.html>
- Myasthenia Gravis
- Myocarditis NASH
- Neurofibromatosis
- Parkinson's Disease* <https://www.fortunebusinessinsights.com/industry-reports/parkinson-s-disease-drugs-market-100655>
- Pemphigus
- Pneumonia Polymyositis
- Post-Myocardial Infarction Syndrome
- Psoriasis
- Rheumatic Fever* <https://www.globenewswire.com/news-release/2020/01/23/1974435/0/en/Rheumatoid-Arthritis-Rheumatoid-Drugs-Market-To-Reach-USD-36-11-Billion-By-2027-Reports-And-Data.html>
- Arthritis*
- Sarcoidosis Scleroderma Sickle Cell Disease (anti-inflammatory effect)
- Sjogren's Syndrome Stroke Tuberculosis Vasculitis
- Kawasaki Syndrom


Cytodyn Disease Project Timeline



STOCK SYMBOL
OTCQB: **CYDY**

Cytodyn Disease Project Timeline for different implication																
Disease/ Year	May 2020 Comp. Use	June 2020 EUA	Covid-19 July 2020	Covid-19 Aug. 2020 Sales	Covid-19 Sept. 2020 Sales	HIV BLA ppr. Oct. 2020 CV-19 Sales	Nov. 2020 CV-19 Sales	HIV PDUFA Dec. 2020 CV-19 Sales	HIV & CV19 Sales 2021	Sales 2022	Sales 2023	Sales 2024	Sales 2025	Sales 2026	Sales 2027 - 2033	
Covid-19				Covid 19- Sales												
Influenza				Infl. appr.				Inf. PDUFA	Influenza Sales							
HIV								HIV appr.& PDUFA	HIV Sales Start							
GHvD									GHvD PDUFA	GHvD Sales						
Cancer (22 ind.)									Cancer appr.	Cancer PDUFA	Cancer Sales					
Asthma & COPD									Asthma & COPD appr.	Asthma & COPD PDUFA	Asthma & COPD Sales					
Athero- sclerosis									Athero- sclerosis appr.	Athero-sclerosis PDUFA	Athero-sclerosis Sales					
Multiple Sclerosis Rheumatoid Arthritis									MS Rheumatoid Arthritis appr.	MS Rheumatoid Arthritis PDUFA	MS Rheumatoid Arthritis Sales					
Other diseases									Other disease appr.	Other disease PDUFA	Other disease Sales					
Alzheimer										Alzheimer appr.	Alzheimer PDUFA	Alzheimer Sales				
Parkinson										Parkinson appr.	Parkinson PDUFA	Parkinson Sales				
Rheumatoid Arthritis										Rheumatoid Arthritis appr.	Rheumatoid Arthritis PDUFA	Rheumatoid Arthritis Sales				
Diabetes type 1										Diabetes type1 appr.	Diabetes type1 PDUFA	Diabetes type1 Sales				
Fybromalgia										Fybromalgia appr.	Fybromalgia PDUFA	Fybromalgia Sales				

Cytodyn Disease Revenue/PPS Vials needed



- Covid approval June 1,2 mn vials at \$ 1,200 vial => in bn revenue
- Cytodyn HIV
- Cytodyn Cancer (22 different implications)
- Cytodyn GHvD
- Cytodyn Diabetes type1
- Cytodyn Asthma & Copd
- Cytodyn Athero-sclerosis
- Cytodyn Rheumatoid Arthritis
- Multiple Sclerosis Rheumatoid Arthritis
- Cytodyn Alzheimer
- Cytodyn Parkinson
- Cytodyn other diseases
- Cytodyn Fybromalgia
- Cytodyn Influenza

Assumptions and opinion of Sunny3999 May 11th 2020

1st Data Cytodyn Disease Revenue/PPS



STOCK SYMBOL
OTCQB: **CYDY**

Assumption market share/year (indication): 1st 3%; 2nd 5%; 3rd 7%; 4th 10%

Cytodyn Revenue Sheet	Leronlimab \$1200/vial	https://www.fortunebusinessinsights.com/industry-		https://www.alliedmarketresearch.com/oncology-				https://www.fortunebusinessinsights.com/industry-		https://www.visiongain.com/report/harma-		https://www.thepharmaletter.com/article/atherosclerosis	
Year	Covid approval June 1,2 vials at \$ 1,200 vial => in bn revenue	HIV worldwide \$ bn revenue	Cytodyn HIV Vyera 50/50	Cancer worldwide revenue	Cytodyn Cancer (22 different implications)	GHVD worldwide revenue	Cytodyn GHvD	Diabetes type1 worldwide \$ bn revenue	Cytodyn Diabetes type1	Asthma & COPD worldwide \$ bn revenue	Cytodyn Asthma & Copd	Atherosclerosis worldwide \$ bn revenue	Cytodyn Atherosclerosis
2018		\$ 25,31		\$ 104,80		\$ 0,40		\$ 48,75		\$ 36,21		\$ 45,70	
2019		\$ 27,03		\$ 112,76		\$ 0,42		\$ 51,72		\$ 37,12		\$ 46,93	
2020	\$ 1,44	\$ 28,87		\$ 121,33		\$ 0,45		\$ 54,88		\$ 38,04		\$ 48,20	
2021	\$ 3,00	\$ 30,83	\$ 1,49	\$ 130,56		\$ 0,48	\$ 0,02	\$ 58,23		\$ 38,99		\$ 49,50	
2022	\$ 5,00	\$ 32,93	\$ 2,54	\$ 140,48	\$ 3,92	\$ 0,50	\$ 0,04	\$ 61,78		\$ 39,97	\$ 1,49	\$ 50,84	\$ 1,49
2023	\$ 7,00	\$ 35,17	\$ 3,65	\$ 151,16	\$ 7,02	\$ 0,54	\$ 0,05	\$ 65,55	\$ 1,75	\$ 40,97	\$ 2,54	\$ 52,21	\$ 2,54
2024	\$ 10,00	\$ 37,56	\$ 5,36	\$ 162,64	\$ 10,58	\$ 0,57	\$ 0,06	\$ 69,55	\$ 3,09	\$ 41,99	\$ 3,65	\$ 53,62	\$ 3,65
2025	\$ 10,50	\$ 40,11	\$ 5,51	\$ 175,00	\$ 16,26	\$ 0,60	\$ 0,06	\$ 73,79	\$ 4,59	\$ 43,04	\$ 5,36	\$ 55,07	\$ 5,36
2026	\$ 11,03	\$ 40,92	\$ 5,66	\$ 178,50	\$ 17,50	\$ 0,64	\$ 0,06	\$ 78,29	\$ 6,95	\$ 44,12	\$ 5,51	\$ 56,56	\$ 5,51
2027	\$ 11,58	\$ 41,73	\$ 5,81	\$ 182,07	\$ 17,85	\$ 0,65	\$ 0,07	\$ 80,25	\$ 7,38	\$ 45,22	\$ 5,66	\$ 58,08	\$ 5,66
2028	\$ 12,16	\$ 42,57	\$ 5,97	\$ 185,72	\$ 18,21	\$ 0,66	\$ 0,07	\$ 82,25	\$ 7,83	\$ 46,35	\$ 5,81	\$ 59,65	\$ 5,81
2029	\$ 12,76	\$ 43,42	\$ 6,13	\$ 189,43	\$ 18,57	\$ 0,68	\$ 0,07	\$ 84,31	\$ 8,02	\$ 47,51	\$ 5,97	\$ 61,26	\$ 5,97
2030	\$ 13,40	\$ 44,29	\$ 6,29	\$ 193,22	\$ 18,94	\$ 0,69	\$ 0,07	\$ 86,42	\$ 8,23	\$ 48,70	\$ 6,13	\$ 62,92	\$ 6,13
2031	\$ 14,07	\$ 45,17	\$ 6,29	\$ 197,08	\$ 19,32	\$ 0,70	\$ 0,07	\$ 88,58	\$ 8,43	\$ 49,92	\$ 6,29	\$ 64,61	\$ 6,29
2032	\$ 14,77	\$ 46,08	\$ 6,29	\$ 201,02	\$ 19,71	\$ 0,72	\$ 0,07	\$ 90,79	\$ 8,64	\$ 51,16	\$ 6,29	\$ 66,36	\$ 6,46
2033	\$ 15,51	\$ 47,00	\$ 7,29	\$ 205,04	\$ 20,10	\$ 0,73	\$ 0,07	\$ 93,06	\$ 8,86	\$ 52,44	\$ 7,29	\$ 68,15	\$ 6,64

2nd Data Cytodyn Disease Revenue/PPS



STOCK SYMBOL
OTCQB: **CYDY**

Assumption market share/year (indication): 1st 3%; 2nd 5%; 3rd 7%; 4th 10%

Cytodyn Revenue Sheet	https://www.medgadget.com/2020/02/multiple-		https://www.ihealthcareanlyst.com/global-		https://www.ihealthcareanlyst.com/global-		https://www.alliedmarketresearch.com/influenza-		https://www.coherentmarketinsights.com/press-		https://www.alliedmarketresearch.com/influenza-		
Year	Cytodyn Rheumatoid Arthritis	Multiple Sclerosis worldwide bn revenue	Multiple Sclerosis Rheumatoid Arthritis	Alzheimer worldwide \$ bn revenue	Cytodyn Alzheimer	Parkinson worldwide \$ bn revenue	Cytodyn Parkinson	Other diseases worldwide \$ bn revenue	Cytodyn other diseases	Fybromalgia worldwide \$ bn revenue	Cytodyn Fybromalgia	Influenza worldwide \$ bn revenue	Cytodyn Influenza
2018		\$ 23,46				\$ 4,50		\$ 10,00		\$ 2,78		\$ 0,86	
2019		\$ 25,03				\$ 4,87		\$ 10,45		\$ 2,87		\$ 0,90	
2020		\$ 26,71		\$ 5,80		\$ 5,28		\$ 10,92		\$ 2,97		\$ 0,94	
2021		\$ 28,50		\$ 7,25		\$ 5,72		\$ 11,41		\$ 3,06		\$ 0,98	\$ 0,03
2022		\$ 30,41	\$ 0,85	\$ 9,06		\$ 6,19		\$ 11,93	\$ 0,05	\$ 3,17		\$ 1,03	\$ 0,05
2023	\$ 0,84	\$ 32,45	\$ 1,52	\$ 11,33	\$ 0,22	\$ 6,70	\$ 0,17	\$ 12,46	\$ 0,11	\$ 3,27	\$ 0,16	\$ 1,07	\$ 0,08
2024	\$ 1,46	\$ 34,62	\$ 2,27	\$ 14,16	\$ 0,45	\$ 7,26	\$ 0,31	\$ 13,02	\$ 0,34	\$ 3,38	\$ 0,23	\$ 1,12	\$ 0,11
2025	\$ 2,13	\$ 36,94	\$ 3,46	\$ 17,70	\$ 0,79	\$ 7,86	\$ 0,47	\$ 13,61	\$ 0,60	\$ 3,49	\$ 0,03	\$ 1,17	\$ 0,12
2026	\$ 3,17	\$ 39,41	\$ 3,69	\$ 18,94	\$ 1,42	\$ 8,52	\$ 0,73	\$ 14,22	\$ 0,87	\$ 3,60	\$ 0,03	\$ 1,23	\$ 0,12
2027	\$ 3,30	\$ 42,05	\$ 3,94	\$ 20,26	\$ 1,77	\$ 9,22	\$ 0,79	\$ 14,65	\$ 1,30	\$ 3,72	\$ 0,04	\$ 1,26	\$ 0,13
2028	\$ 3,44	\$ 44,87	\$ 4,21	\$ 21,68	\$ 1,89	\$ 9,99	\$ 0,85	\$ 15,09	\$ 1,36	\$ 3,85	\$ 0,04	\$ 1,30	\$ 0,13
2029	\$ 3,58	\$ 47,88	\$ 4,49	\$ 23,20	\$ 2,03	\$ 10,82	\$ 0,92	\$ 15,54	\$ 1,42	\$ 3,97	\$ 0,04	\$ 1,34	\$ 0,13
2030	\$ 3,73	\$ 51,09	\$ 4,79	\$ 24,83	\$ 2,17	\$ 11,72	\$ 1,00	\$ 16,01	\$ 1,46	\$ 4,10	\$ 0,04	\$ 1,38	\$ 0,14
2031	\$ 3,88	\$ 54,51	\$ 5,11	\$ 26,56	\$ 2,32	\$ 12,69	\$ 1,08	\$ 16,49	\$ 1,51	\$ 4,24	\$ 0,04	\$ 1,42	\$ 0,14
2032	\$ 4,04	\$ 58,16	\$ 5,45	\$ 28,42	\$ 2,48	\$ 13,74	\$ 1,17	\$ 16,98	\$ 1,55	\$ 4,38	\$ 0,04	\$ 1,46	\$ 0,15
2033	\$ 4,20	\$ 62,06	\$ 5,82	\$ 30,41	\$ 2,66	\$ 14,88	\$ 1,27	\$ 17,49	\$ 1,60	\$ 4,52	\$ 0,04	\$ 1,51	\$ 0,15

Pharma Market Revenue disease* / Cytodyn Revenue -PPS – Vials Needed

- PPS in 2020
considers Covid-19:
- ✓ Comp. use (May)
 - ✓ EUA (June)
 - ✓ Sales June-Dez.
 - ✓ 1,2 mn vials
 - ✓ \$1200
 - ✓ \$1,44 bn sales

Year	Pharma in bn \$ Market Revenue	vials needed in mn	Cytodyn PPS
2018	\$ 327,71		
2019	\$ 346,08		
2020	\$ 365,62	1,20	\$ 17,93
2021	\$ 386,40	3,76	\$ 35,17
2022	\$ 408,50	12,84	\$ 70,09
2023	\$ 432,03	23,03	\$ 125,74
2024	\$ 457,07	34,62	\$ 189,02
2025	\$ 483,73	46,04	\$ 251,36
2026	\$ 500,40	51,87	\$ 283,23
2027	\$ 514,72	54,38	\$ 296,90
2028	\$ 529,57	56,46	\$ 308,28
2029	\$ 544,96	58,41	\$ 318,91
2030	\$ 560,91	60,42	\$ 329,89
2031	\$ 577,46	62,37	\$ 340,55
2032	\$ 594,63	64,27	\$ 350,91
2033	\$ 612,46	67,92	\$ 370,84

This Database,
Revenue and
PPS is only an
example and
should not be
considered as
given.

It contains
future
assumptions
and my own
opinions!



STOCK SYMBOL
OTCQB: **CYDY**

Thank you for
your attention
& feedback for
details or your
assumptions!